Radboud Repository

      View Item 
      •   Radboud Repository
      • Collections Radboud University
      • Datasets
      • View Item
      •   Radboud Repository
      • Collections Radboud University
      • Datasets
      • View Item
      JavaScript is disabled for your browser. Some features of this site may not work without it.
      BrowseAll of RepositoryCollectionsDepartmentsDate IssuedAuthorsTitlesDocument typeThis CollectionDepartmentsDate IssuedAuthorsTitlesDocument type
      StatisticsView Item Statistics

      The enhancing effects of testosterone in exposure treatment for social anxiety disorder: a randomized proof-of-concept trial 2017-2021

      Find Full text
      Creators
      Hutschemaekers, M.H.M.
      Roelofs, K.
      Kleine, R.A. de
      Kampman, M.
      Hendriks, G.J.
      Date of Archiving
      2021
      Archive
      Radboud Data Repository
      DOI
      https://doi.org/10.34973/z5pf-p041
      Related publications
      The enhancing effects of testosterone in exposure treatment for social anxiety disorder: A randomized proof-of-concept trial  
      Publication type
      Dataset
      Access level
      Restricted access
      Please use this identifier to cite or link to this item: https://hdl.handle.net/2066/239502   https://hdl.handle.net/2066/239502
      Display more detailsDisplay less details
      Organization
      SW OZ BSI KLP
      PI Group Affective Neuroscience
      Audience(s)
      Psychology
      Languages used
      English
      Key words
      Testosterone; Fear; Social anxiety disorder
      Abstract
      This dataset contains the analyzed variables for the paper: The enhancing effects of testosterone in exposure treatment for social anxiety disorder: a randomized proof-of-concept trial. For example descriptives of participants, subjective units of distress ratings, during exposure, hormone data and social anxiety symptom ratings.Abstract of paper:Individuals with a social anxiety disorder (SAD) show hypofunctioning of the hypothalamus–pituitary-gonadal (HPG) axis, which islinked to social fear and avoidance behavior. As testosterone administration has been shown to facilitate social-approach behaviorin this population, it may enhance the effectiveness of exposure treatment. In this proof-of-concept study, we performed arandomized clinical assay in which 55 women diagnosed with SAD received two exposure therapy sessions. Session 1 wassupplemented with either testosterone (0.50 mg) or placebo. Next, transfer effects of testosterone augmentation on withinsessionsubjective fear responses and SAD symptom severity were assessed during a second, unenhanced exposure session(session 2) and at a 1-month follow-up, respectively. The participants having received testosterone showed a more reactive fearpattern, with higher peaks and steeper reductions in fear levels in session 2. Post-hoc exploration of moderating effects ofendogenous testosterone levels, revealed that this pattern was specific for women with high basal testosterone, both in theaugmented and in the transfer session. In contrast, the participants with low endogenous testosterone showed reduced peak fearlevels throughout session 1, again with transfer to the unenhanced session. Testosterone did not significantly affect self-reportedanxiety. The effects of testosterone supplementation on fear levels show transfer to non-enhanced exposure, with effects beingmodulated by endogenous testosterone. These first preliminary results indicate that testosterone may act on important fearmechanisms during exposure, providing the empirical groundwork for further exploration of multi-session testosterone-enhancedexposure treatment for SAD.
      This item appears in the following Collection(s)
      • Datasets [1446]
      • Donders Centre for Cognitive Neuroimaging [3609]
      • Faculty of Social Sciences [28533]
       
      •  Upload Full Text
      •  Terms of Use
      •  Notice and Takedown
      Bookmark and Share
      Admin login